Filters

Calcium Polycarbophil API Suppliers - Manufacturers and Distributors

Find verified Calcium Polycarbophil API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Calcium Polycarbophil for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Calcium Polycarbophil API.

Calcium Polycarbophil

Alternate Names: Fibercon, Mitrolan, Polycarbophil, calcium

CAS No: 9003-97-8

Mol Formula: [–CH(COOH)–CH₂–]ₙ Ca²⁺

Mol Weight: 238.20 g/mol

IUPAC Name: 3,4-dihydroxy-1,5-hexadiene crosslinked calcium polyacrylate   - Show More

API Description: Calcium Polycarbophil is a loosely cross-linked synthetic polycarboxylic-type hydrophilic polymer resin, laxative and anti-diarrheal Calcium Polycarbophil increases stool frequency, fecal water content, and fecal weight in a dose-dependent manner. It is used for idiopathic constipation, secretory diarrhea, and irritable bowel syndrome.

Calcium Polycarbophil

List of Calcium Polycarbophil API Suppliers - Manufacturers and Distributors

Certificates


Countries


Suppliers


Grade

The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate c lture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim....The Boehringer Ingelheim group of companies objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. - Show More

CoAUSDMF

Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in t e national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulatio...Zhejiang Hisoar Pharmaceutical Co., Ltd. is located in Taizhou, Zhejiang. It is an IPO-listed company held by the DanKong Group, which mainly manufactures APIs, Formulations, Fine Chemicals, Dyestuffs, and Dyestuff Intermediates. It is one of the top 100 innovative companies in the national pharmaceutical industry. The main product categories are antibiotics, cardiovascular, hypoglycemic, and others, fine chemicals, formulations, dyes, and intermediates. More than 70% of pharmaceutical products are exported, in which Clindamycin series production is in the leading position worldwide. - Show More

CoAUSDMF

Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is a leading position in the manufacturing technology and capacity for antipyre ics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular syst...Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is a leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates. - Show More

CoAUSDMF

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the ame year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY ...Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market. - Show More

CoAUSDMF